HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Hematology · IDH Inhibition Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Hematology · IDH Inhibition Competitive Landscape

19 findings · 85 signals · 12 insights

Type

Competitive Landscape Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 81%

Evidence

104 items

Sources

6

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Hematology · IDH Inhibition synthesizes 19 Competitiva findings across 85 active signals. 8 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Pfizer — Fabhalta

    Pfizer is a regulatory competitive threat because recent agency-facing activity on Fabhalta in Hematology · Complement Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    View detail
  2. competitive

    Roche — AZD0120

    Roche is a direct competitive threat because it is already approved in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.

    View detail
  3. competitive

    Roche — AZD0120

    Roche is a direct competitive threat because it is already approved in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.

    View detail
  4. competitive

    Bristol Myers Squibb — AZD0120

    Bristol Myers Squibb is a direct competitive threat because it has a Phase III program in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.

    View detail
  5. competitive

    Pfizer — AZD0120

    Pfizer is an emerging emerging competitor with Phase I activity on AZD0120 in Hematology · Multiple Myeloma; while behind AstraZeneca (Phase I), accelerated readouts could compress AstraZeneca's strategic window.

    View detail
  6. competitive

    Roche — ianalumab

    Roche is a regulatory competitive threat because recent agency-facing activity on ianalumab in Hematology · Immune Thrombocytopenia may reset approval benchmarks and timeline expectations for Novartis.

    View detail
  7. competitive

    Roche — ianalumab

    Roche is a regulatory competitive threat because recent agency-facing activity on ianalumab in Hematology · Immune Thrombocytopenia may reset approval benchmarks and timeline expectations for Novartis.

    View detail
  8. competitive

    Merck — ianalumab

    Merck is a direct competitive threat because it has a Phase III program in Hematology · Immune Thrombocytopenia (ianalumab) and could narrow Novartis's development lead.

    View detail
  9. competitive

    Roche — ianalumab

    Roche is a regulatory competitive threat because recent agency-facing activity on ianalumab in Hematology · Immune Thrombocytopenia may reset approval benchmarks and timeline expectations for Novartis.

    View detail
  10. competitive

    Pfizer — REVLIMID

    Pfizer is a regulatory competitive threat because recent agency-facing activity on REVLIMID in Hematology · Multiple Myeloma may reset approval benchmarks and timeline expectations for Bristol Myers Squibb.

    View detail
  11. competitive

    Roche — asciminib

    Roche is a direct competitive threat because it is already approved in Hematology · Chronic Myeloid Leukemia (asciminib) and could narrow Novartis's development lead.

    View detail
  12. competitive

    Roche — asciminib

    Roche is a direct competitive threat because it is already approved in Hematology · Chronic Myeloid Leukemia (asciminib) and could narrow Novartis's development lead.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 8 high-pressure competitive programs for portfolio displacement risk. Cross-reference 12 executive insights for synthesized strategic assessment. Leading competitive pressure: High across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Pfizer — Fabhalta

    74%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on Fabhalta in Hematology · Complement Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    Source: Pfizer

    View evidence

  • Roche — AZD0120

    74%

    Roche is a direct competitive threat because it is already approved in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.

    Source: Roche

    View evidence

  • Roche — AZD0120

    74%

    Roche is a direct competitive threat because it is already approved in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.

    Source: Roche

    View evidence

  • Bristol Myers Squibb — AZD0120

    83%

    Bristol Myers Squibb is a direct competitive threat because it has a Phase III program in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.

    Source: Bristol Myers Squibb

    View evidence

  • Pfizer — AZD0120

    95%

    Pfizer is an emerging emerging competitor with Phase I activity on AZD0120 in Hematology · Multiple Myeloma; while behind AstraZeneca (Phase I), accelerated readouts could compress AstraZeneca's strategic window.

    Source: Pfizer

    View evidence

  • Roche — ianalumab

    81%

    Roche is a regulatory competitive threat because recent agency-facing activity on ianalumab in Hematology · Immune Thrombocytopenia may reset approval benchmarks and timeline expectations for Novartis.

    Source: Roche

    View evidence

  • Roche — ianalumab

    81%

    Roche is a regulatory competitive threat because recent agency-facing activity on ianalumab in Hematology · Immune Thrombocytopenia may reset approval benchmarks and timeline expectations for Novartis.

    Source: Roche

    View evidence

  • Merck — ianalumab

    81%

    Merck is a direct competitive threat because it has a Phase III program in Hematology · Immune Thrombocytopenia (ianalumab) and could narrow Novartis's development lead.

    Source: Merck

    View evidence

  • Roche — ianalumab

    95%

    Roche is a regulatory competitive threat because recent agency-facing activity on ianalumab in Hematology · Immune Thrombocytopenia may reset approval benchmarks and timeline expectations for Novartis.

    Source: Humanexa Signals

    View evidence

  • Pfizer — REVLIMID

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on REVLIMID in Hematology · Multiple Myeloma may reset approval benchmarks and timeline expectations for Bristol Myers Squibb.

    Source: Pfizer

    View evidence

  • Roche — asciminib

    80%

    Roche is a direct competitive threat because it is already approved in Hematology · Chronic Myeloid Leukemia (asciminib) and could narrow Novartis's development lead.

    Source: Roche

    View evidence

  • Roche — asciminib

    80%

    Roche is a direct competitive threat because it is already approved in Hematology · Chronic Myeloid Leukemia (asciminib) and could narrow Novartis's development lead.

    Source: Roche

    View evidence

  • Bristol Myers Squibb — asciminib

    69%

    Bristol Myers Squibb is an emerging emerging competitor with Phase I activity on asciminib in Hematology · Chronic Myeloid Leukemia; while behind Novartis (development-stage), accelerated readouts could compress Novartis's strategic window.

    Source: Bristol Myers Squibb

    View evidence

  • Lilly — asciminib

    95%

    Lilly is a regulatory competitive threat because recent agency-facing activity on asciminib in Hematology · Chronic Myeloid Leukemia may reset approval benchmarks and timeline expectations for Novartis.

    Source: Lilly

    View evidence

  • Merck — Marstacimab

    70%

    Merck is a regulatory competitive threat because recent agency-facing activity on Marstacimab in Hematology · Monoclonal Antibody may reset approval benchmarks and timeline expectations for Pfizer.

    Source: Merck

    View evidence

  • Merck — Marstacimab

    80%

    Merck is a regulatory competitive threat because recent agency-facing activity on Marstacimab in Hematology · Monoclonal Antibody may reset approval benchmarks and timeline expectations for Pfizer.

    Source: Merck

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)

    Regulatory Approval

  • Lilly to acquire Ajax Therapeutics for myelofibrosis and polycythemia vera

    M&A / Partnership

  • FDA Approves JAKAFI XR for Incyte Corp.

    Regulatory Approval

  • FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma

    Regulatory Approval

  • Elranatamab shows robust efficacy and favorable safety in relapsed/refractory multiple myeloma

    Regulatory Approval

  • MHRA Approves UK Plasma Donations for Key Medicinal Products

    Regulatory Approval

  • Risk of Severe Harm from Incorrect Blood Transfusion Administration Sets

    Safety Signal

  • FDA Approves Casgevy for Young Children with Sickle Cell Disease

    Regulatory Approval

Insights

  • Growing Competitive Landscape in CAR-T Cell Therapy for Acute Lymphoblastic Leukemia

    Hematology · CAR-T Cell Therapy

  • Eli Lilly Strengthens Hematology Portfolio with Ajax Acquisition to Compete in JAK2 Inhibition

    Hematology · JAK2 Inhibition

  • Telerehabilitation Trial Could Transform Hemophilia Treatment Landscape

    Hematology · Hemophilia

  • Critical Safety Signal in Blood Transfusion Practices Demands Urgent Regulatory Review

    Hematology · Blood Transfusion

  • Enhancing Hydroxyurea Adoption in Nigeria: Strategic Implications for Sickle Cell Treatments

    Hematology · Sickle Cell Disease

  • BESREMI's FDA Application Acceptance Enhances Competitive Position in Rare Blood Disorders

    Hematology · Rare Blood Disorders

  • Emerging Generic Competition in Hematology: Strategic Implications for Market Players

    Hematology · Thrombocytopenia

  • Eli Lilly and Agios Pharmaceuticals: Competitive Dynamics in Hematology and Thalassemia

    Hematology · CLL

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Merck

    132 signals

  • AstraZeneca

    127 signals

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Bristol Myers Squibb

    38 signals

  • Janssen

    36 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.